Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ovarian cancer (stage III or IV) that is high-grade serous or endometrioid type.
- You have a positive HRD test result, which indicates your cancer may respond to this combination.
- Your doctor has determined that upfront surgery is not the best first step, so neoadjuvant (pre-surgery) therapy is appropriate.
- You have at least one measurable tumor and are expected to live at least 12 weeks.
- You are between 18 and 75 years old and have good overall health (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy or with targeted therapy (Olaparib) given before surgery for advanced ovarian cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients who are not candidates for immediate surgery.
This trial tests a combination of three drugs (olaparib, durvalumab, and bevacizumab) given before surgery for women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if this treatment shrinks the cancer enough to allow successful surgery.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This trial tests two drugs (fluzoparib with famitinib or SHR-1701) given before surgery to shrink advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if these treatments can make tumors small enough for complete removal or improve the surgery outcome.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests whether olaparib and durvalumab given around the time of diagnosis can help people with advanced ovarian cancer. It also strongly focuses on collecting tumor and blood samples to better understand who may benefit.
Hear when a new Ovary Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.